Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could feeding ICU patients in short bursts save their muscles?

NCT ID NCT03587870

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether giving protein-rich formula in short bursts (intermittent feeding) is better than the standard continuous drip for preventing muscle loss in critically ill patients. 113 ICU adults expected to stay at least 5 days were randomly assigned to one of the two feeding methods. Researchers measured how quickly patients reached their daily protein goal and tracked muscle changes with ultrasound and biopsies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Fresubin Intensive (protein-rich enteral nutrition formula)
What this could lead to
If intermittent feeding works better, it could become a simpler, more natural way to prevent muscle loss in ICU patients and speed up recovery.
What could go wrong
This is a small pilot study, so results may not be conclusive. The two groups also get different protein targets, which could affect comparisons.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

113 people

The number who actually took part.

Started

Mar 2019

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Informed Consent as documented by signature * Adult patients (age 18 years or older) * Expected ICU stay of five days or longer * Expected enteral feeding during at least five days Exclusion Criteria: * Pregnancy or breast feeding (women of childbearing age are tested for high beta-human chorionic gonadotropin (hCG) in urine or serum upon ICU admission) * Clinically significant chronic or acute kidney insufficiency with a glomerular filtration rate (GFR) \<15. * BMI ≤ 18 and ≥ 35. * Intestinal perforation, peritonitis, intestinal fistula, necrosis or other contraindication to enteral diet * Death or discharge before 48 hours of observation * Noradrenaline ≥ 0.5 µg/kg bodyweight /min * Inherited and chronic skeletal muscle disease (e.g. Morbus Duchenne or other motoneuron disease) * Paralysis (e.g. hemiplegia, tetraplegia and paraplegia) * Immunosuppression * Haematologic malignancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Muscle wasting in critically ill are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University Hospital Basel, operative ICU

    Basel, Canton of Basel-City, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.